What Nanobiotix S.A. does.

We are a late-stage clinical biotechnology company focused on re-inventing medicine by building new therapies atom by atom, developing widely applicable, first-in-class, physics-based nanotherapeutics to transform treatment outcomes and expand life for millions of patients. The physics-based nanotherapeutics we create are potentially universally applicable across patient populations, rather than targeted to impact a specific biological pathway in a particular patient. The objective of this physics-based approach is to allow our nanoparticles to be combined with other drugs or therapeutic modalities and to integrate seamlessly into clinical practice without adding burden for the patient, healthcare provider, or healthcare system.

• Nanoradioenhancer platform: Designed to increase the tumor-killing effect of radiotherapy without increasing the dose in surrounding healthy tissues;

• Nanoprimer platform: Designed to unleash the potential of innovative systemic therapeutic classes by enabling effective extrahepatic delivery;

Revenue and profit, by fiscal year.

More on NBTX.

• Nanobiotix S.A. summary
• Nanobiotix S.A. financial statements
• Nanobiotix S.A. key metrics
• Nanobiotix S.A. health scores and style box
• Nanobiotix S.A. earnings
• Nanobiotix S.A. dividends
• Nanobiotix S.A. valuation
• Nanobiotix S.A. ownership and insiders
• Nanobiotix S.A. peers

Figures from Nanobiotix S.A.'s filings with the U.S. SEC, standardised automatically; prices are end-of-day closes. Not financial advice.